Entera Biotech is a clinical-stage biopharmaceutical company developing first-in-class oral tablet formulations of peptides and protein replacement therapies for chronic medical conditions where injectable alternatives currently dominate. The company's pipeline includes EB613 (oral teriparatide for osteoporosis), EB612 (oral PTH for hypoparathyroidism), and collaborative programs targeting obesity and short bowel syndrome, all enabled by its proprietary N-Tab® platform technology designed to stabilize large peptides and enhance their absorption in the gastrointestinal tract—overcoming the longstanding technical challenge that has limited oral protein therapies. Entera retains full global rights to its lead program and holds equity stakes in collaborative programs with OPKO Biologics, generating value through partnerships and potential royalties as candidates advance through clinical development and regulatory approval, though the company remains pre-revenue with no approved commercial products.